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Experimental allergic encephalomyelitis (EAE) is an inflammatory disease of 
the central nervous system (CNS) that resembles human multiple sclerosis 
(MS). EAE and MS develop when proteins of the myelin sheath that covers axons 
are released and encounter cells of the immune system such as T lymphocytes. 
Activation of these lymphocytes will trigger inflammation that destroys the 
myelin leading to clinical signs that manifest mostly in the form of motion 
impairment and muscle paralysis. Inactivation of myelin specific lymphocytes 
is currently viewed as a means to halt immune attack against the brain and 
reverse the course of disease. In this study we devised an antigen specific 
approach against EAE and tested its efficacy in an advanced genetic setting, 
which would better represent the human genetic polymorphism. Therefore, we 
have created an F1(SJL/J x Bl/6) mouse for analysis of the reversal of 
compatible as well as “in trans” EAE where the disease is induced by a 
peptide restricted to one parent and the treatment uses a fusion protein 
carrying a peptide restricted to the other parent. The results indicate that 
the effectiveness of the treatment depends on the method of disease induction 
and the genetic makeup of the mouse.  
 
